Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous Watanabe hyperlipidemic rabbits

Journal of Vascular Research

Volumn 37, Issue 3, 2000, Pages 189-194

  Pauletto, Paolo ^a   Puato, Massimo ^a   Faggin, Elisabetta ^a   Sartore, Saverio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

3 Hydroxy 3 methylglutaryl CoA reductase inhibitor; Atherosclerosis; Cerivastatin; Heterozygous Watanabe heritable hyperlipidemia rabbit; Macrophage; Smooth muscle cell

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER;

EID: 0034120095     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025730     Document Type: Article

References (15)

1. Zanellato AMC, Borrione AC, Tonello M, Scannapieco G, Pauletto P, Sartore S: Myosin isoform expression and smooth muscle cell heterogeneity in normal and atherosclerotic rabbit aorta. Arteriosclerosis 1990;10:996-1009.
2. Sartore S, Chiavegato A, Faggin E, Pauletto P: Myosin gene expression and cell heterogeneity in developing and adult smooth muscle and in vascular disease. Arterioscler Thromb Vasc Biol 1997;17:1210-1215.
3. Pauletto P, Scannapicco G, Borrione AC, Zanellato AMC, Tonello M, Giuriato L, Pessina AC, Dal Palù C, Sartore S: A nifedipine-sensitive smooth muscle cell population is present in the atherosclerotic rabbit aorta. Arterioscler Thromb 1991;11:928-939.
4. Pauletto P, Sartore S, Giuriato L, Scatena M, Guidolin D, Scannapieco G, Pessina AC: Computer-driven assessment of 'immature' type smooth muscle cells in rabbit aorta. J Hypertens 1991;9(suppl 6):S180-S181.
5. Giuriato L, Scatena M, Chiavegato A, Zanellato AM, Guidolin D, Pauletto P, Sartore S: Localization and smooth muscle cell composition of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1993;13:347-359.
6. Stein EA: Extending therapy options in treating lipid disorders: A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Drugs 1998;56(suppl 1):25-31.
7. Shiomi M, Ito T: Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999;126: 961-968.
8. Tsukada T, Rosenfeld M, Ross R, Gown AM: Immunocytochemical analysis of cellular components in atherosclerotic lesions: Use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis 1986;6:601-613.
9. Giuriato L, Chiavegato A, Pauletto P, Sartore S: Correlation between the presence of an immature smooth muscle cell population in tunica media and the development of atherosclerotic lesion. A study on different-sized rabbit arteries from cholesterol-fed and Watanabe heritable hyperlipemic rabbits. Atherosclerosis 1995;116:77-92.
10. Esper E, Runge WJ, Gunther R, Buchwald H: Natural history of atherosclerosis and hyperlipidemia in heterozygous WHHL (WHHL-Hh) rabbits. II. Morphologic evaluation of spontaneously occurring aortic and coronary lesions. J Lab Clin Med 1993;121:103-110.
11. Atkinson JB, Virmani R, Harrison J, Swift L: Pathology of atherosclerosis in heterozygous. Watanabe heritable hyperlipidemic rabbits Arteriosclerosis 1985;5:524a.
12. Brasen JH, Harsch M, Niendorf A: Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet. Virchows Arch 1998;432:557-562.
13. Harsch M, Gebhardt A, Reymann A, Lang G, Schliack M, Loser R, Braesen JH, Niendorf A: Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits. Br J Pharmacol 1998;124:277-282.
14. Igarashi M, Takeda Y, Mori S, Ishibashi N, Komatsu E, Takahashi K, Fuse T, Yamamura M, Kubo K, Sugiyama Y, Saito Y: Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228 and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997;120 1172-1178.
15. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137(suppl):S101-S109.